Clear Street raised the firm’s price target on Editas Medicine (EDIT) to $4.60 from $4 and keeps a Buy rating on the shares following the Q3 report. The company maintained previously stated timelines for EDIT-401, the analyst tells investors in a research note. The firm sees $1.8B in peak sales and a 10% likelihood of success.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Editas Medicine reports Q3 EPS (28c), consensus (38c)
- Editas Medicine Inc. (EDIT) Q3 Earnings Cheat Sheet
- FDA to speed up gene editing therapy approvals, Bloomberg reports
- Video: This stock is dragging down the in vivo gene editing therapy space
- Editas Medicine’s Long-Term Study on EDIT-301: A Potential Game-Changer for Hemoglobinopathies